Compare Incyte Corporation (INCY) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Sunrun Inc — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.65B), while Sunrun Inc trades at $10.13 (market cap $2.38B). The key difference: Incyte Corporation is far larger — about 10.4× Sunrun Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| INCY | RUN | |
|---|---|---|
Market Cap | $24.65B | $2.38B |
Sector | Health | Technology |
52-Week High | $129.93 | $21.41 |
52-Week Low | $81.61 | $9.38 |
Enterprise Value | $20.15B | $16.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.56, up 1.84% on the day, near its 52-week high of $120.70. The stock shows a bullish technical trend with strong earnings beats in Q1 and Q2 2026, including Q2 EPS of $3.09 versus $2.15 expected. Revenue growth accelerated to $5.14 billion in 2025, with a net income margin of 27.71%. Recent news highlights EU approval for Opzelura and a raised 2026 revenue outlook, fueling positive momentum.
The outlook remains favorable with analyst consensus at Buy and a $122.82 price target, though risks include reliance on key drugs like Jakafi and competitive pressures. Earnings growth and pipeline advancements support upside, but investors should monitor execution against guidance and regulatory developments.
Sunrun (RUN) trades at $10.20, up 8.74% in 24 hours, with a bearish technical signal and mixed sentiment. The company reported Q2 2026 EPS of $0.42, beating estimates, but shares fell due to guidance cuts. Valuation ratios appear attractive with a P/E of 6.71 and P/S of 0.77, while net income margin stands at 11.59%.
Outlook is cautious; analyst consensus is bullish with a $14.38 price target, but risks include negative operating cash flow, high debt, and competitive pressures. Near-term performance hinges on execution amid sector volatility and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
